Among the most significant changes in health care during the pandemic has been the acceptance of digital therapeutics that may transform care pathways.
One of the companies pioneering the new prescription digital therapeutics (PDT) market is Pear Therapeutics, which has commercialized three of its PDTs: Somryst, which is prescribed to treat...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?